Cart summary

You have no items in your shopping cart.

SU11274

SKU: orb1224320

Description

SU11274 (PKI-SU11274) is a potent, selective, ATP-competitive c-Met kinase inhibitor with IC50 of 20 nM, >50-fold selectivity over Bcr-Abl, JAK2, PDGFβR; induces G(1) cell cycle arrest and apoptosis with increased Annexin V staining and caspase 3 activity, specifically regulates cell growth in TPR-MET-transformed BaF3 cells with IC50 of <3 uM, differentially affects the kinase activity and subsequent signaling of various mutant forms of Met (M1268T and H1112Y).

Images & Validation

Key Properties

CAS Number658084-23-2
MW568.0869
Purity>98% (HPLC)
FormulaC28H30ClN5O4S
SMILESO=S(C1=CC2=C(NC(/C2=C\C3=C(C)C(C(N4CCN(C)CC4)=O)=C(C)N3)=O)C=C1)(N(C5=CC=CC(Cl)=C5)C)=O
Targetc-Met/HGFR
Solubility10 mM in DMSO

Bioactivity

In Vitro
SU11274 exhibits greater than 50-fold selectivity for Met versus Flk and more than 500 times selectivity versus other tyrosine kinases such as FGFR-1, c-src, PDGFbR, and EGFR. SU11274 inhibits the phosphorylation of key regulators of the PI3K pathway, including AKT, FKHR, or GSK3β. SU11274 treatment inhibits the growth of TPR-MET-transformed BaF3 cells in a dose-dependent manner with IC50 of < 3 μM in the absence of interleukin 3, without growth inhibition of BaF3 cells transformed by other oncogenic tyrosine kinases, including BCR-ABL, TEL-JAK2, TEL-ABL, and TEL-PDGFβR. In addition to cell growth, SU11274 treatment significantly inhibits the migration of BaF3. TPR-MET cells by 44.8% and 80% at 1 μM and 5 μM, respectively. SU11274 inhibits HGF-dependent phosphorylation of Met as well as HGF-dependent cell proliferation and motility with an IC50 of 1-1.5 μM. In H69 and H345 cells which have functional Met receptor, SU11274 inhibits the HGF-induced cell growth with IC50 of 3.4 μM and 6.5 μM, respectively. SU11274 induces G1 cell cycle arrest with cells in G1 phase increased from 42.4% to 70.6% at 5 μM, and induces caspase-dependent apoptosis by 24% at 1 μM. SU11274 inhibits cell viability in c-Met-expressing non-small cell lung cancer (NSCLC) cells with IC50 values of 0.8-4.4 μM, and abrogates hepatocyte growth factor-induced phosphorylation of c-Met and its downstream signaling.

Storage & Handling

StorageStorage temperature: -20°C. Stability: ≥ 2 years
Expiration Date12 months from date of receipt.
DisclaimerFor research use only

Alternative Names

SU 11274 | PKI-SU11274 | SU-11274

Similar Products

  • SU11274 [orb1301028]

    99.44%

    658084-23-2

    568.09

    C28H30ClN5O4S

    2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 1 mg, 1 ml x 10 mM (in DMSO)
Quality Guarantee

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at support@biorbyt.com.

Documents Download

Datasheet
Product Information
Download

Request a Document

Protocol Information

SU11274 (orb1224320)

  • Star
  • Star
  • Star
  • Star
  • Star
  • 0.0
Based on 0 reviews

Participating in our Biorbyt product reviews program enables you to support fellow scientists by sharing your firsthand experience with our products.

Login to Submit a Review

No reviews yet

Step 1: Enter information below

(Recommended: An additional animal making an allowance for loss during the experiment)

Step 2: Enter the in vivo formulation

(This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO +
%+
% Tween 80 +
%

Available Sizes

Select a size below

200 mg
500 mg
2 mg
$ 100.00
5 mg
$ 160.00
10 mg
$ 230.00
25 mg
$ 410.00
50 mg
$ 660.00
100 mg
$ 960.00